LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

Search

Viatris Inc

Suletud

SektorTervishoid

9.12 2.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.01

Max

9.13

Põhinäitajad

By Trading Economics

Sissetulek

-2.5B

-3B

Müük

-274M

3.3B

Aktsiakasum

0.5

Dividenditootlus

5.42

Kasumimarginaal

-93.476

Töötajad

32,000

EBITDA

-2.7B

-2.3B

Soovitused

By TipRanks

Soovitused

Müü

12 kuu keskmine prognoos

+1.24% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.42%

2.40%

Järgmine tulemuste avaldamine

7. aug 2025

Järgmine dividendimakse kuupäev

12. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

22. aug 2025

Turustatistika

By TradingEconomics

Turukapital

539M

10B

Eelmine avamishind

6.53

Eelmine sulgemishind

9.12

Uudiste sentiment

By Acuity

50%

50%

154 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Viatris Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2025, 23:49 UTC

Tulu

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. juuni 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. juuni 2025, 21:30 UTC

Tulu

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Tulu

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. juuni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. juuni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. juuni 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. juuni 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. juuni 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. juuni 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. juuni 2025, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. juuni 2025, 22:06 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:15 UTC

Tulu

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. juuni 2025, 21:07 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. juuni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 20:52 UTC

Tulu

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. juuni 2025, 20:51 UTC

Tulu

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Viatris Inc Prognoos

Hinnasiht

By TipRanks

1.24% tõus

12 kuu keskmine prognoos

Keskmine 9 USD  1.24%

Kõrge 10 USD

Madal 8 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Viatris Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

3 ratings

0

Osta

2

Hoia

1

Müü

Tehniline skoor

By Trading Central

8.48 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

154 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.